Eton Pharmaceuticals, Inc.
NASDAQ:ETON
16.79 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 39.011 | 31.642 | 21.251 | 21.832 | 0.039 | 0.959 | 0 | 0 |
| Cost of Revenue
| 15.6 | 10.581 | 6.933 | 2.623 | 0.286 | 0.453 | 0.063 | 0.013 |
| Gross Profit
| 23.411 | 21.061 | 14.318 | 19.209 | -0.247 | 0.506 | -0.063 | -0.013 |
| Gross Profit Ratio
| 0.6 | 0.666 | 0.674 | 0.88 | -6.333 | 0.528 | 0 | 0 |
| Reseach & Development Expenses
| 3.255 | 3.322 | 3.996 | 6.235 | 14.104 | 11.555 | 5.627 | 3.93 |
| General & Administrative Expenses
| 22.753 | 18.931 | 18.582 | 14.469 | 12.76 | 7.552 | 4.694 | 4.83 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.623 |
| SG&A
| 22.753 | 18.931 | 18.582 | 14.469 | 12.76 | 7.552 | 4.694 | 3.207 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 26.008 | 22.253 | 22.578 | 20.704 | 26.864 | 19.107 | 10.321 | 7.137 |
| Operating Income
| -2.597 | -1.192 | -8.26 | -1.495 | -27.111 | -18.601 | -10.321 | -7.15 |
| Operating Income Ratio
| -0.067 | -0.038 | -0.389 | -0.068 | -695.154 | -19.396 | 0 | 0 |
| Total Other Income Expenses Net
| -1.211 | 0.503 | -0.761 | -0.46 | -0.859 | 0.281 | -2.419 | -0.006 |
| Income Before Tax
| -3.808 | -0.689 | -9.021 | -1.955 | -27.97 | -18.32 | -12.74 | -7.156 |
| Income Before Tax Ratio
| -0.098 | -0.022 | -0.424 | -0.09 | -717.179 | -19.103 | 0 | 0 |
| Income Tax Expense
| 0.015 | 0.247 | 0.761 | 1.006 | 0.859 | -0.281 | -2.583 | 0 |
| Net Income
| -3.823 | -0.936 | -9.782 | -2.961 | -28.829 | -18.039 | -12.74 | -7.156 |
| Net Income Ratio
| -0.098 | -0.03 | -0.46 | -0.136 | -739.205 | -18.81 | 0 | 0 |
| EPS
| -0.15 | -0.037 | -0.39 | -0.12 | -1.37 | -1.02 | -1.99 | -0.41 |
| EPS Diluted
| -0.15 | -0.037 | -0.39 | -0.12 | -1.37 | -1.02 | -1.99 | -0.41 |
| EBITDA
| -1.451 | -0.291 | -6.486 | -1.121 | -26.46 | -18.154 | -10.258 | -7.143 |
| EBITDA Ratio
| -0.037 | -0.009 | -0.305 | -0.051 | -678.462 | -18.93 | 0 | 0 |